ev3 receives Class I notice for US catheter recall
This article was originally published in Clinica
The US FDA has given ev3’s recall of certain lots of its NanoCross .014" PTA balloon catheter as Class I notification – the most serious type of recall notice. The FDA action was prompted by a letter sent by ev3 to its customers in November that said there is potential for the device to crack during use. The Plymouth, Minnesota-based company said that breaking of the catheter shaft can result in its inability to inflate or deflate the balloon, thus possibly causing injury or death. The company has asked for all affected lots – manufactured from 27 May to 18 October 2010 – to be removed from use. The NanoCross catheter is designed to dilate stenoses in the iliac, femoral, iliofemoral, popliteal, infra-popliteal and renal arteries.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals